Pitavastatin lowers plaque volume, progression in lower-risk patients with HIV

By Erik Swain

Pitavastatin lowered noncalcified plaque volume and reduced risk for plaque progression compared with placebo in patients with HIV at low to moderate risk for CVD, according to new data from the REPRIEVE trial.

Read the full article here here.